Unicon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-01-2025
- Paid Up Capital ₹ 0.10 M
as on 04-01-2025
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.65 M
as on 04-01-2025
- Revenue 61.36%
(FY 2023)
- Profit 410.76%
(FY 2023)
- Ebitda 222.50%
(FY 2023)
- Net Worth 2801.08%
(FY 2023)
- Total Assets 24.20%
(FY 2023)
About Unicon Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹7.65 M.
Ravi Kollipora, Udaya Perla, and Ramesh Modukuri serve as directors at the Company.
- CIN/LLPIN
U24100TG2020PTC143959
- Company No.
143959
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Unicon Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Udaya Perla  | Managing Director | 16-Sep-2020 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramesh Modukuri | Director | 16-Sep-2020 | Current |
| Ravi Kollipora | Director | 18-Nov-2020 | Current |
Financial Performance of Unicon Pharma.
Unicon Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 61.36% increase. The company also saw a substantial improvement in profitability, with a 410.76% increase in profit. The company's net worth Soared by an impressive increase of 2801.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unicon Pharma?
Unlock access to Unicon Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Unistar Pharma Private LimitedActive 1 year 9 monthsRavi Kollipora and Udaya Perla are mutual person
- Sarath Meditech Private LimitedActive 2 years 3 months
Udaya Perla and Ramesh Modukuri are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 27 Mar 2024 | ₹7.65 M | Open |
How Many Employees Work at Unicon Pharma?
Unlock and access historical data on people associated with Unicon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unicon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unicon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
